The study provides a detailed analysis of the industry, including the global calcium market trends, share, size, and in ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

More data leads to more precise answers, and the biopharma industry has at its disposal more data than ever before.

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

U.S. exchange operators are in talks with the Securities and Exchanges Commission on easing regulatory burdens for public companies, as they seek to encourage more richly valued startups to list, ...

I was scrolling through TikTok one evening and stumbled on a video promoting an herbal product that claimed to “prevent pregnancy naturally,” even going as far as saying, “you won’t get pregnant even ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced an updated timeline for submitting its Biologics ...

Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway ...